Summary of findings 8. SSRIs compared to NaSSAs for adults with panic disorder.
| SSRIs compared to NaSSAs for adults with panic disorder | ||||||
| Patient or population: adults with panic disorder Settings: outpatient Intervention: SSRI Comparison: NaSSA | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| NaSSA | SSRI | |||||
| failure to respond | See comment | See comment | Not estimable | 0 (0) | See comment | |
| total number of dropouts Follow‐up: 8 weeks | 133 per 1000 | 200 per 1000 (39 to 1000) | RR 1.50 (0.29 to 7.73) | 30 (1 study) | ⊕⊕⊝⊝ low1 | |
| failure to remit | See comment | See comment | Not estimable | 0 (0) | See comment | No studies provided data for this outcome |
| panic symptoms Follow‐up: 8 weeks | The mean panic symptoms in the intervention groups was 0.30 higher (0.49 lower to 1.09 higher) | 22 (1 study) | ⊕⊕⊝⊝ low2 | |||
| number of dropouts due to adverse events Follow‐up: 8 weeks | 133 per 1000 | 200 per 1000 (39 to 1000) | RR 1.50 (0.29 to 7.73) | 30 (1 study) | ⊕⊕⊝⊝ low1 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 30) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data 2 Downgraded two points due to imprecision: number of individuals included in the trial is very low (= 22) and 95% CI is very wide, ranging from appreciable benefit with SSRIs to appreciable benefit with NaSSAs; only one study provides data